Abstract:This study tested the hypothesis that GLP‐1 based therapies improve cardiac contractile function at rest and in response to beta‐adrenergic stimulation in an obese swine model of ischemic heart disease. Ossabaw swine were fed a high calorie, obesogenic diet for 6 months. Following this period, swine were subjected to a gradually developing coronary occlusion by placement of an ameroid occluder on the left anterior descending (LAD) coronary artery. Animals then received daily subcutaneous injections of saline or the stable GLP‐1 analogue liraglutide (0.005–0.015mg/kg/day) for 30 days. Following this treatment, animals were anesthetized and an open chest procedure was performed to assess cardiac performance in response to a sympathomimetic challenge (dobutamine 0.3–10 μg/kg/min) using a left ventricular pressure/volume admittance catheter. Liraglutide administration did not influence the magnitude of myocardial infarction in response to LAD occlusion (saline 16 ± 2% vs liraglutide 14 ± 4%; P = 0.8). Baseline cardiac output and ejection fraction were not different between treatment groups at rest or in response to dobutamine. Thirty days of treatment with liraglutide did not modify the effects of dobutamine to increase pulse pressure, heart rate, dP/dtmax, or contractility index. Indices of diastolic relaxation during dobutamine stimulation were augmented in liraglutide treated animals (dP/dt min P < 0.001, Tau 1⁄2 P <0.001, Tau 1/e P < 0.001). Dobutamine reduced left ventricular end diastolic volume, end systolic volume, and stroke volume similarly in saline and liraglutide treated animals. However, the slope of the end systolic pressure volume relationship (ESPVR; load‐independent contractility) was significantly increased by dobutamine following liraglutide (4.2 ± 1.1 vs 21.8 ± 8.4 mmHg/ml; P <0.001) but not saline (8.7 ± 5.9 vs 14.8 ± 3.5 mmHg/ml; P = 0.63). Dobutamine increased the volume axis intercept (Vo) of ESPVR in both groups, but this effect was ~50% smaller in animals treated with liraglutide at the lower dobutamine infusion rates (0.3 and 1 μg/kg/min; P < 0.05). While cardiac efficiency (stroke work/pressure volume area) was similar between treatment groups at baseline (70 ± 7% vs 69 ± 3; P = 0.92), liraglutide significantly enhanced cardiac efficiency under the highest dobutamine infusion rate (10 μg/kg/min; P = 0.017). Taken together, these data suggest that GLP‐1 agonism augments diastolic relaxation, contractility, and cardiac efficiency under sympathetic stimulation in the setting of obesity and regional myocardial infarction. Support or Funding Information This study was supported by R01HL11760 (J. Tune and K. Mather, PI). Dr. Goodwill was supported by American Heart Association 13POST1681001813 (A. Goodwill, PI). Ms. Noblet and Mr. Sassoon were supported by TL1 TR000162 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award.

Liraglutide ameliorates TAC-induced cardiac hypertrophy and heart failure by upregulating expression level of ANP expression

LncRNA TUG1 Alleviates Cardiac Hypertrophy by Targeting Mir‐34a/dkk1/wnt‐β‐catenin Signalling

The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling

Exogenous supplement of glucagon like peptide-1 protects the heart against aortic banding induced myocardial fibrosis and dysfunction through inhibiting mTOR/p70S6K signaling and promoting autophagy

Effects of liraglutide on ANP secretion and cardiac dynamics

Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation

Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome

Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE -/- mice

Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways

[The Renal Protective Effect and Mechanism of Liraglutide in Diabetic Mice Induced by High-Fat Diet].

LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice

Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update

Liraglutide Protects Cardiomyocytes against Isoprenaline-Induced Apoptosis in Experimental Takotsubo Syndrome

The Long Acting GLP‐1 Receptor Agonist, Liraglutide, Augments Myocardial Contractile Responses and Cardiac Efficiency Under Sympathetic Stimulation in Obesity and Myocardial Infarction

Gentianella acuta improves TAC-induced cardiac remodelling by regulating the Notch and PI3K/Akt/FOXO1/3 pathways

Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways

Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

LITAF acts as a novel regulator for pathological cardiac hypertrophy

Liraglutide Reduces Hepatic Glucolipotoxicity‑induced Liver Cell Apoptosis Through NRF2 Signaling in Zucker Diabetic Fatty Rats